Infliximab in young paediatric IBD patients: it is all about the dosing

Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in inflammatory bowel disease (IBD) patients. Our hypothesis is that especially young children need a more intensive treatment regimen than the current weight-based dose administration. We aimed to assess IFX pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongsma, Maria M. E., Winter, Dwight A., Huynh, Hien Q., Norsa, Lorenzo, Hussey, Seamus, Kolho, Kaija-Leena, Bronsky, Jiri, Assa, Amit, Cohen, Shlomi, Lev-Tzion, Raffi, Van Biervliet, Stephanie, Rizopoulos, Dimitris, de Meij, Tim G. J., Shouval, Dror S., Wine, Eytan, Wolters, Victorien M., Martinez-Vinson, Christine, de Ridder, Lissy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666662/
https://www.ncbi.nlm.nih.gov/pubmed/32813123
http://dx.doi.org/10.1007/s00431-020-03750-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666662/
https://www.ncbi.nlm.nih.gov/pubmed/32813123
http://dx.doi.org/10.1007/s00431-020-03750-0

Ejemplares similares